The pacing system is implanted directly inside the heart’s right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates, according to an April 4 news release. It allows cardiologists to measure electrical signals and determine the correct device placement before final implantation through its mapping capabilities.
“The Aveir VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options,” said Randel Woodgrift, senior vice president of cardiac rhythm management at Abbott. “Our goal is to continue to build on the success of Aveir to provide more first-of-their-kind products in the future, revolutionizing how abnormal heart rhythms are treated.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
